What to Know About Tysabri and PML Risk
From General Health Education to Occupational Exposure Awareness
If you or a loved one is taking Tysabri and experiencing new neurological symptoms like confusion, vision changes, or weakness, it's natural to be concerned about the risk of progressive multifocal leukoencephalopathy (PML). Medical understanding of drug safety has evolved through decades of clinical observation and post-market surveillance. This page provides a clear overview of what is currently known about Tysabri-associated PML, including early warning signs and monitoring recommendations.
Understanding Tysabri and Its Association with PML
Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn's disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by the JC virus (JCV) and typically occurs only in patients who are immunocompromised (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three factors are known to increase the risk of PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Clinical Evidence and Adverse Event Reports
In clinical trials, PML occurred in three patients who received Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Two cases were observed in the 1869 patients with multiple sclerosis who were treated for a median of 120 weeks; these two patients had received Tysabri in addition to interferon beta-1a (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The third case occurred after eight doses in one of the 1043 patients with Crohn's disease who were evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). FDA FAERS adverse-event reports most frequently associated with Tysabri include fatigue (19150 reports), multiple sclerosis relapse (16691 reports), headache (9626 reports), multiple sclerosis (9580 reports), gait disturbance (9422 reports), fall (7939 reports), memory impairment (7895 reports), asthenia (7852 reports), malaise (7319 reports), drug ineffective (6813 reports), urinary tract infection (6192 reports), pain (5852 reports), balance disorder (5621 reports), hypoesthesia (5343 reports), pain in extremity (4849 reports), muscular weakness (4535 reports), nasopharyngitis (4423 reports), nausea (4203 reports), dizziness (3944 reports), mobility decreased (3769 reports), stress (3542 reports), cognitive disorder (3478 reports), muscle spasms (3152 reports), depression (3091 reports), and arthralgia (2992 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI).
Mechanism of PML and Risk Factors
The mechanistic pathway linking Tysabri to PML involves its pharmacological action. Tysabri is an alpha-4 integrin antagonist that inhibits the migration of immune cells into the brain. This immunosuppressive effect can allow the JC virus, which is normally controlled by the immune system, to reactivate and cause PML. The risk is particularly elevated in patients with anti-JCV antibodies, as these antibodies indicate prior exposure to the virus. Longer treatment duration, especially beyond 2 years, further increases the risk, as does prior use of immunosuppressants, which may already compromise immune function. The adequacy of warnings regarding Tysabri and PML is a key consideration. The boxed warning clearly states that Tysabri increases the risk of PML and that it usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). It also identifies the three risk factors and instructs healthcare professionals to monitor patients and withhold Tysabri at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, despite these warnings, PML continues to occur in patients, raising questions about whether the warnings are sufficient to ensure informed decision-making and timely intervention.
Legal Considerations for Affected Individuals
For patients affected by PML, attorney-related considerations are important. Individuals who develop PML after taking Tysabri may seek legal recourse to address the harm they have suffered. The timeline between exposure and documented harm is critical in such cases. PML can develop after varying durations of Tysabri treatment, with risk increasing beyond 2 years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In clinical trials, PML occurred after a median of 120 weeks in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This variability underscores the need for careful monitoring and prompt action if symptoms arise. In summary, Tysabri is associated with a well-documented risk of PML, a severe and often fatal brain infection. The prescribing information includes a boxed warning and identifies risk factors, but PML cases continue to occur. Patients who develop PML may face significant medical and legal challenges, and understanding the timeline and risk factors is essential for both clinical management and potential legal action.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is Tysabri and what is it used for?
Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn's disease. It works by inhibiting the migration of immune cells into the brain, which can reduce inflammation but also increases the risk of progressive multifocal leukoencephalopathy (PML).
What is PML and how is it linked to Tysabri?
Progressive multifocal leukoencephalopathy (PML) is a rare but serious brain infection caused by the JC virus. Tysabri increases the risk of PML by suppressing the immune system, allowing the virus to reactivate. The risk is higher in patients with anti-JCV antibodies, longer treatment duration (especially over 2 years), and prior use of immunosuppressants.
What are the symptoms of PML?
Symptoms of PML can include progressive weakness on one side of the body, clumsiness, vision changes, confusion, and personality changes. Because PML can lead to severe disability or death, immediate medical attention is crucial if any new neurological symptoms appear during Tysabri treatment.
Can I file a lawsuit if I developed PML after taking Tysabri?
Individuals who develop PML after Tysabri treatment may be eligible to seek legal compensation for their injuries. An attorney can help evaluate the case, considering factors such as the adequacy of warnings, the timeline of exposure, and the presence of risk factors. It is important to consult with a lawyer experienced in pharmaceutical litigation.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.